Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Outlook Therapeutics priced a public offering of 55.6 million shares of common stock and accompanying warrants at $0.99 per unit, targeting $55 million in gross proceeds. The company intends to use the net proceeds to support the U.S. commercial launch of LYTENAVA, as well as for working capital and general corporate purposes.
Key figures
- Deal Value Usd
- 55000000
- Offering Price
- 0.99
- Shares Offered
- 55555556
- Warrants offered
- 55555556
- Warrant exercise price
- 1.1
- Warrant expiration years
- 5
- Underwriters option shares
- 8333333
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.